A retrospective study: Effects of additional SGLT2-inhibitor therapy on renal functions in patients with type 2 diabetes mellitus and stage 3b and 4 chronic kidney disease
Not Applicable
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000035278
- Lead Sponsor
- Jinnouchi Hospital Diabetes Care Center
- Brief Summary
We analyzed 42 T2DM patients with median GFR of 40.4 mL/min/1.73 m2. The annual decline in eGFR improved significantly after SGLT2 inhibitor therapy (eGFR: (median), pre: -3.8, vs. post: 0.1 mL/min/1.73 m2 per year, P < 0.01). We also found a significant decrease in urinary protein excretion after SGLT2 inhibitor therapy (urinary protein-to-creatinine ratio: (median), pre: 0.36, vs. post: 0.23 g/g creatinine, n = 35, P < 0.01).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
type 1 DM cancer auto-immune disease active inflammation dimentia
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement of annual changes in eGFR
- Secondary Outcome Measures
Name Time Method improvement of urinary protein decrease in HbA1c